KCM
TVTX icon

Kingdon Capital Management’s Travere Therapeutics TVTX Stock Holding History

Kingdon Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.94M Buy
+200,000
New +$5.98M 0.65% 51

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kingdon Capital Management's TVTX Position: Q1 2017 in Review

Kingdon Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 413,591 shares — an estimated $7.83M sold.

Kingdon Capital Management first reported a position in TVTX in Q3 2016 and held it in 2 quarters. The position peaked at $8.51M in Q3 2016. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

  • Kingdon Capital Management reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Kingdon Capital Management sold 413,591 Travere Therapeutics shares in Q1 2017, an estimated $7.83M.
  • Kingdon Capital Management first reported a position in Travere Therapeutics in Q3 2016 and held it in 2 quarters.
  • Kingdon Capital Management's Travere Therapeutics position peaked at $8.51M in Q3 2016.
  • 114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Kingdon Capital Management's 13F filing for Q1 2017, filed 15 May 2017.